BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. World J Methodol 2015; 5(4): 212-215 [PMID: 26713281 DOI: 10.5662/wjm.v5.i4.212]
URL: https://www.wjgnet.com/2222-0682/full/v5/i4/212.htm
Number Citing Articles
1
Tess Van Meerhaeghe, Alexandre Cez, Karine Dahan, Emmanuel Esteve, Ismail Elalamy, Jean Jacques Boffa, Eleonore Ponlot. Apixaban Prophylactic Anticoagulation in Patients with Nephrotic SyndromeTH Open 2022; 6(04): e299 doi: 10.1055/a-1920-6224
2
Ekta Yogeshkumar Pandya, Elizabeth Anderson, Clara Chow, Yishen Wang, Beata Bajorek. Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital settingTherapeutic Advances in Drug Safety 2018; 9(2): 97 doi: 10.1177/2042098617744926
3
Howard H. Z. Thom, Will Hollingworth, Reecha Sofat, Zhenru Wang, Wei Fang, Pritesh N. Bodalia, Peter A. Bryden, Philippa A. Davies, Deborah M. Caldwell, Sofia Dias, Diane Eaton, Julian P. T. Higgins, Aroon D. Hingorani, Jose A. Lopez-Lopez, George N. Okoli, Alison Richards, Chris Salisbury, Jelena Savović, Annya Stephens-Boal, Jonathan A. C. Sterne, Nicky J. Welton. Directly Acting Oral Anticoagulants for the Prevention of Stroke in Atrial Fibrillation in England and Wales: Cost-Effectiveness Model and Value of Information AnalysisMDM Policy & Practice 2019; 4(2): 238146831986682 doi: 10.1177/2381468319866828
4
Mario González‐Sales, Lanyan Fang, Myong‐Jin Kim, Liang Zhao. Model‐Based Assessment Using Conventional Bioequivalence Limits to Ensure Safety and Efficacy of Rivaroxaban in Patients Undergoing Hip or Knee ReplacementThe Journal of Clinical Pharmacology 2017; 57(12): 1591 doi: 10.1002/jcph.930
5
Robbert Bipat. Phytochemicals in Human Health2020;  doi: 10.5772/intechopen.89765
6
Alireza Ghodsi, Leila Etemad, Bita Dadpour, Babak Mostafazadeh, Mohammad Moshiri. Conservative management of massive rivaroxaban overdose: A case report and literature reviewClinical Case Reports 2021; 9(11) doi: 10.1002/ccr3.5023
7
Michael B. Simmers, Banumathi K. Cole, Martin L. Ogletree, Zhu Chen, Yiming Xu, Ling-jie Kong, Nigel Mackman, Brett R. Blackman, Brian R. Wamhoff. Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cellsThrombosis Research 2016; 143: 34 doi: 10.1016/j.thromres.2016.04.022
8
Sinan Cem Uzunget, Togay Evrin, Sezen Baglan Uzunget, Zamir Kemal Ertürk, Egemen Akıncıoğlu, Saffet Özdemir, Atila Korkmaz. Evaluation of activated charcoal and lipid emulsion treatment in model of acute rivaroxaban toxicityThe American Journal of Emergency Medicine 2018; 36(8): 1346 doi: 10.1016/j.ajem.2017.12.039
9
Jean Terrier, Youssef Daali, Pierre Fontana, Chantal Csajka, Jean-Luc Reny. Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral AnticoagulantsClinical Pharmacokinetics 2019; 58(12): 1517 doi: 10.1007/s40262-019-00792-y
10
Tony Kim, Matthew Finkelman, Bhavik Desai, Arwa Farag. Direct‐acting oral anti‐coagulants in dental practice: A Retrospective Observational Study (Part 1)Oral Diseases 2021; 27(4): 1052 doi: 10.1111/odi.13604
11
Aastha Gupta, D. S. Udayakumar, Renu Saxena. Hematopathology2019; : 377 doi: 10.1007/978-981-13-7713-6_22